|

Using Chronobiology to Improve Lenvatinib Efficacy

RECRUITINGEarly 1Sponsored by Hadassah Medical Organization
Actively Recruiting
PhaseEarly 1
SponsorHadassah Medical Organization
Started2023-03-01
Est. completion2024-04
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06321120

Summary

The goal of this proof-of-concept clinical trial is to assess the efficacy and safety of chronobiology implementation into lenvatinib treatment regimens of thyroid cancer patients, via a mobile application. Participants will use a mobile application to follow variability-based physician approved drug administration schedules.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Age 18-80 years
2. Lenvatinib treated cancer patients, who suffer from loss of response of dose-limiting adverse effects.

Exclusion Criteria:

1. Current or history of drug abuse
2. Pregnancy/lactation/planned pregnancy
3. The subject is currently enrolled in or has not yet completed at least 60 days since ending another investigational device or drug trial.
4. Unable to comply with study requirements.

Conditions2

CancerLenvatinib Treatment

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.